Media Advisory: Surescripts to Present on Innovative Interoperability at 2025 Nourishing Change Conference Hosted by Kroger Health, May 13-15
ARLINGTON, Va.--(BUSINESS WIRE)--Surescripts ®, the nation's leading health intelligence network, will present on healthcare interoperability as part of a panel of healthcare leaders at the 2025 Nourishing Change Conference hosted by Kroger Health, May 13-15 in Cincinnati, Ohio.
'I can't wait to join industry leaders at the 2025 Nourishing Change Conference to share insights & discuss how we can focus on innovations that make a meaningful difference for patients," said Melanie Marcus, Chief Marketing & Customer Experience Officer.
Share
'I can't wait to join industry leaders as part of a panel at the 2025 Nourishing Change Conference to share insights and discuss how we can continue to focus on innovations that make a meaningful difference for patients and the people who serve them,' said Melanie Marcus, Chief Marketing and Customer Experience Officer for Surescripts.
'Healthcare is facing serious challenges, from provider burnout to patients not being able to access or afford care. It's a challenge that collaboration and innovation that advances health intelligence sharing can help solve. When clinicians and care providers are better informed, it accelerates decisions, keeping patient care on track," added Marcus.
To learn more, check out the panel discussion:
What Does Optimal Interoperability Look Like?
When: May 14, 2025, 2:00-3:15PM
Location: Breakout Sessions--Part One
Overview: What would it take for every part of the health system to connect and communicate? This session explores the path to true interoperability—what it looks like in practice, where it's already working, and how we expand its impact across every community.
Panelists: Melanie Marcus, Surescripts, Yousuf Ahmad, AssureCare, David Pope, XiFin Pharmacy Solutions and moderator, Elizabeth Koonin, UnitedHealthcare.
Background:
In 2024, Surescripts supported 27.2 billion exchanges of patient clinical and benefit information, enabling 2.29 million healthcare professionals and organizations with access to clinical and benefit information for virtually every insured American.
Health intelligence sharing at scale is helping to increase patient safety, lower costs and improve the quality of care by enabling:
2.6 billion electronic prescriptions to be delivered in 2024, helping patients get needed medications faster and safer.
Nearly 900,000 prescribers with technology like Real-Time Prescription Benefit to saving patients an average of $82 per prescription and more than $1,000 per specialty medication.
Touchless Prior Authorization, improving efficiency for care providers and reducing the average time to approve a prior authorization from more than one hour to just 34 seconds, helping patients get needed medications faster.
For more information about how Surescripts is helping improve healthcare for patients and the people who serve them, check out Surescripts 2024 Annual Impact Report.
About Surescripts
Our purpose is to serve the nation through simpler, trusted health intelligence sharing, in order to increase patient safety, lower costs and ensure quality care. At Surescripts, we bring healthcare together to inform and accelerate decisions, helping keep patient care on track. With the Surescripts Network Alliance®, we're empowering the healthcare ecosystem with intelligence and interoperability for smarter, faster prescribing, prior authorization, treatment, care management and more. Visit us at surescripts.com and follow us on LinkedIn.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass., June 08, 2025--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; "Modalis"), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. "SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD," stated Eva Chin, Executive Director of SOLVE FSHD. "SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials." "We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103," said Haru Morita, CEO of Modalis. "This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD." About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit About Modalis Therapeutics Corporation Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit View source version on Contacts SOLVE FSHDAlexandra Grant, House of Wilsonalexandrag@ Modalis Therapeutics CorporationCorporate Planning Departmentmedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
2 hours ago
- Business Wire
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)-- SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; 'Modalis'), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM ® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM ® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. 'SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD,' stated Eva Chin, Executive Director of SOLVE FSHD. 'SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials.' 'We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103,' said Haru Morita, CEO of Modalis. 'This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM ® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM ® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD.' About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM ® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit
Boston Globe
2 hours ago
- Boston Globe
Palestinians say Israeli fire kills 12 near aid sites
Advertisement Eleven of the latest bodies were brought to Nasser Hospital in the southern city of Khan Younis. Palestinian witnesses said Israeli forces fired on some at a roundabout around a kilometer (half-mile) from a site run by the Gaza Humanitarian Foundation, or GHF, in nearby Rafah. Israel's military said it fired warning shots at approaching 'suspects' who ignored warnings to turn away. It said the shooting happened in an area that is considered an active combat zone at night. Al-Awda Hospital said it received the body of a man and 29 people who were wounded near another GHF aid distribution point in central Gaza. The military said it fired warning shots in the area at around 6:40 a.m., but didn't see any casualties. Advertisement A GHF official said there was no violence in or around its distribution sites, all three of which delivered aid on Sunday. The group closed them temporarily last week to discuss safety measures with Israel's military and has warned people to stay on designated access routes. The official spoke on condition of anonymity in line with regulations. The new aid hubs are set up inside Israeli military zones where independent media have no access. The GHF also said it was piloting direct delivery to a community north of Rafah. Witnesses said the first shootings in southern Gaza took place at around 6 a.m., when they were told the site would open. Many headed toward it early, seeking desperately needed food before crowds arrived. Gaza's roughly 2 million Palestinians are almost completely reliant on international aid because nearly all food production capabilities have been destroyed. Adham Dahman, who was at Nasser Hospital with a bandage on his chin, said a tank fired toward them. 'We didn't know how to escape,' he said. 'This is [a] trap for us, not aid.' Zahed Ben Hassan said someone next to him was shot in the head. 'They said it was a safe area from 6 a.m. until 6 p.m. ... So why did they start shooting at us?' he said. 'There was light out, and they have their cameras and can clearly see us.' The military announced on Friday that the sites would be open during those hours, and the areas would be a closed military zone the rest of the time. Children cried over their father's body at the hospital. 'I can't see you like this, Dad!' one girl said. Advertisement The new aid hubs are run by GHF, a new group of mainly American contractors. Israel wants it to replace a system coordinated by the United Nations and international aid groups. Israel and the United States accuse the Hamas militant group of stealing aid. The UN denies there is systematic diversion. The UN says the new system is unable to meet mounting needs, allows Israel to use aid as a weapon by determining who can receive it and forces people to relocate to where aid sites are positioned. The UN system has struggled to deliver aid, even after Israel eased its blockade of Gaza last month. UN officials say their efforts are hindered by Israeli military restrictions, the breakdown of law and order and widespread looting. Experts warned earlier this year that Gaza was at critical risk of famine, if Israel didn't lift its blockade and halt its military campaign. Both were renewed in March. Israeli officials have said the offensive will continue until all hostages are returned and Hamas is defeated or disarmed and sent into exile. On Sunday, Israel's military invited journalists into Khan Younis to show a tunnel under the European Hospital, saying they found the body of Mohammed Sinwar, the head of Hamas' armed wing, there after he was killed last month. Israel has barred international journalists from entering Gaza independently since the war began. '(Israeli forces) would prefer not to hit or target hospitals,' army spokesperson Brig. Gen. Effie Defrin said. Sinwar's body was found in a room under the hospital's emergency room, Defrin said. Hamas has said it will only release the remaining hostages in return for Palestinian prisoners, a lasting ceasefire and an Israeli withdrawal from Gaza. Talks mediated by the U.S., Egypt, and Qatar have been deadlocked for months. Advertisement Hamas started the war with its attack on southern Israel on Oct. 7, 2023, when Palestinian militants killed around 1,200 people, mostly civilians, and took another 251 hostage. They still hold 55 hostages, fewer than half of them alive, after most of the rest were released in ceasefire agreements or other deals. Israel's military campaign has killed more than 54,800 Palestinians, according to Gaza's Health Ministry. It says women and children make up most of the dead, but doesn't say how many civilians or combatants were killed. Israel says it has killed more than 20,000 militants, without providing evidence. The war has destroyed vast areas of Gaza and displaced around 90 percent of its population.
